AnaptysBio
Open
$57.78
Prev. Close
$57.72
High
$57.78
Low
$57.43
Market Snapshot
$1.66B
-61.8
-5.15
$91.28M
104
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2017-01-26. The firm manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The firm's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The firm's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2017-01-26. The firm manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The firm's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The firm's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
Recently from Cashu
AnaptysBio Shifts to Royalty-Focused Model After First Tracks Spin-Off for Financial Stability
AnaptysBio (Ticker: ANAB) announces a strategic pivot towards a royalty-focused business model following the spin-off of First Tracks Biotherapeutics, aiming to enhance its financial stability and sha…
AnaptysBio Completes Spin-Off, Shifts Focus to Managing Royalty Collaborations and Streamlined Operations
AnaptysBio (ANAB) has recently announced the successful completion of its spin-off of First Tracks Biotherapeutics, marking a significant strategic shift in its operational focus. AnaptysBio's Strateg…
Vanda Pharmaceuticals Advances AnaptysBio with BLA Submission for Imsidolimab in Rare Disease
Vanda Pharmaceuticals Advances Rare Disease Treatment with BLA Submission for Imsidolimab Vanda Pharmaceuticals Inc. takes a significant step in the treatment of rare inflammatory skin conditions by s…
AnaptysBio Advances Rare Disease Treatment with BLA Submission for Imsidolimab in GPP
Vanda Pharmaceuticals Advances Rare Disease Treatment with BLA Submission for Imsidolimab Vanda Pharmaceuticals Inc. makes a significant move in the biopharmaceutical landscape with the submission of…